Biotech
Twist Bioscience
Twist Bioscience raises $200M Convertible Note at $4B valuation
$200M
Total Raised
Convertible Note
Latest Round
2013
Founded
600+
Employees
681 Gateway Boulevard, South San Francisco, CA 94080
1 min read
Quick Facts
Valuation
$4B
Latest Round Size
$200M
Latest Round Date
April 2024
Twist Bioscience: Convertible Note Funding Round
Twist Bioscience has successfully raised $200M in Convertible Note funding, reaching a valuation of $4B.
Company Overview
Synthetic DNA manufacturing
Funding Details
The Convertible Note round was led by Temasek Holdings, with participation from Fidelity, Paladin Capital Group, Casdin Capital.
Company Information
- Headquarters: 681 Gateway Boulevard, South San Francisco, CA 94080
- Founded: 2013
- Employees: 600+
- Category: Biotech
Investment
Twist Bioscience plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Temasek Holdings: Verified investor in Convertible Note
- Fidelity: Verified investor in Convertible Note
- Paladin Capital Group: Verified investor in Convertible Note
- Casdin Capital: Verified investor in Convertible Note
Key Investors
Temasek Holdings
Lead Investor
Verified investor in Convertible Note
Fidelity
Investor
Verified investor in Convertible Note
Paladin Capital Group
Investor
Verified investor in Convertible Note
Casdin Capital
Investor
Verified investor in Convertible Note
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M